1Systematic Review2017
Brennan R, Wells JSG, Van Hout MC · Health Soc Care Community (2017)
Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
8 peer-reviewed studies
What the evidence says
Most Melanotan-1 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 1988–2017 with a typical study size of 77 participants.
Based on 8 studies · 3 RCTs · 77 total participants
Confidence
Moderate confidenceBy outcome
Newest study from 2017
Brennan R, Wells JSG, Van Hout MC · Health Soc Care Community (2017)
Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME · Biopharm Drug Dispos (1997)
Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB · Arch Dermatol (2004)
In plain English: Afamelanotide, the α-MSH analog, reduces dermal phototoxicity in erythropoietic protoporphyria.
Minder, Schneider-Yin · Expert review of clinical pharmacology (2015)
In plain English: Melanotan (NDP-MSH) bound the MC1 receptor and significantly increased the eumelanin content of human skin, including in individuals with MC1R variants.
Fitzgerald, Fryer, Dwyer, Humphrey · Peptides (2006)
In plain English: Melanotropic peptides are more than just 'Barbie drugs' and 'sun-tan jabs'.
Langan, Nie, Rhodes · The British journal of dermatology (2010)
In plain English: An α-MSH analogue provided systemic photoprotection in solar urticaria.
Haylett, Nie, Brownrigg, Taylor, Rhodes · The British journal of dermatology (2011)
In plain English: Toxicologic studies characterized the superpotent α-melanotropin [Nle4, D-Phe7]-α-MSH in mice.
Dorr, Dawson, al-Obeidi, Hadley, Levine, Hruby · Investigational new drugs (1988)